Meanwhile, ligand-receptor interactions between THY1 (CD90) and ITGAX/ITGB2 (CD11C/CD18) were observed from glioma cells (Clusters C1, C2, and C4) to TAMs (Cluster C0) (Fig. 1g, h). Here, ITGAX is linked to central nervous system cancer.